Antigen Identification Using SEREX

  • Ugur Sahin
  • Özlem Türeci
Part of the Methods in Molecular Biology book series (MIMB, volume 1061)


Serological analysis of recombinant cDNA expression libraries (SEREX) allows systematic identification of antigens recognized by the spontaneous autoantibody repertoire of patients with cancer and autoimmune disease. SEREX is based on screening of lambda phage expression libraries constructed from diseased tissue with the autologous patient’s serum. This chapter provides the key protocols for SEREX immunoscreening and for downstream validation of autoantigens.

Key words

SEREX Autoantibodies Serology Autoantigens Expression cloning Immunoproteomics Biomarker 


  1. 1.
    Sahin U, Türeci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M (1995) Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A 92:11810–11813PubMedCrossRefGoogle Scholar
  2. 2.
    Rauch J, Gires O (2008) SEREX, Proteomex, AMIDA, and beyond: serological screening technologies for target identification. Proteomics Clin Appl 2:355–371PubMedCrossRefGoogle Scholar
  3. 3.
    Krebs P, Kurrer M, Sahin U, Türeci O, Ludewig B (2003) Autoimmunity seen through the SEREX-scope. Autoimmun Rev 2(6):339–345PubMedCrossRefGoogle Scholar
  4. 4.
    Old LJ, Chen YT (1998) New paths in human cancer serology. J Exp Med 187:1163–1167PubMedCrossRefGoogle Scholar
  5. 5.
    Chomczynski P, Sacchi N (1987) Anal Biochem 162:156–159PubMedCrossRefGoogle Scholar
  6. 6.
    Diatchenko L, Lukyanov S, Lau YF, Siebert PD (1999) Suppression subtractive hybridisation: a versatile method for identifying differentially expressed genes. Methods Enzymol 303:349–380PubMedCrossRefGoogle Scholar
  7. 7.
    Türeci Ö, Schmitt H, Fadle N, Pfreundschuh M, Sahin U (1997) Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin’s disease. J Biol Chem 272:6416–6422PubMedCrossRefGoogle Scholar
  8. 8.
    Stockert E, Jäger E, Chen YT, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A, Old LJ (1998) A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187:1349–1354PubMedCrossRefGoogle Scholar
  9. 9.
    Lagarkova MA, Koroleva EP, Kuprash DV, Boitchenko VE, Kashkarova UA, Nedospasov SA, Shebzukhov YV (2003) Evaluation of humoral response to tumor antigens using recombinant expression-based serological mini-arrays (SMARTA). Immunol Lett 85:71–74PubMedCrossRefGoogle Scholar
  10. 10.
    Scanlan MJ, Welt S, Gordon CM, Chen YT, Gure AO, Stockert E, Jungbluth AA, Ritter G, Jager D, Jager E, Knuth A, Old LJ (2002) Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res 62:4041–4047PubMedGoogle Scholar
  11. 11.
    Türeci Ö, Luxemburger U, Heinen H, Mack U, Ukena D, Sybrecht GW, Huber C, Sahin U (2006) CrELISA: a fast and robust enzyme linked immuno sorbent assay bypassing the need for purification of recombinant protein. Cancer Lett 236:64–71PubMedCrossRefGoogle Scholar
  12. 12.
    Gnjatic S, Wheeler C, Ebner M, Ritter E, Murray A, Altorki NK, Ferrara CA, Hepburne-Scott H, Joyce S, Koopman J, McAndrew MB, Workman N, Ritter G, Fallon R, Old LJ (2009) Seromic analysis of antibody responses in non-small cell lung cancer patients and healthy donors using conformational protein arrays. J Immunol Methods 341:50–58PubMedCrossRefGoogle Scholar
  13. 13.
    Krause P, Türeci Ö, Micke P, Buhl R, Huber C, Sahin U (2003) SeroGRID: an improved method for the rapid selection of antigens with disease related immunogenicity. J Immunol Methods 283:261–267PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2013

Authors and Affiliations

  • Ugur Sahin
    • 1
  • Özlem Türeci
    • 2
  1. 1.Translational Oncology (TRON)MainzGermany
  2. 2.Translational Oncology at the University HospitalMainzGermany

Personalised recommendations